IGF1 and neoplasm: Using a genetic mouse model, the CSF-1R inhibitor BLZ945 caused an acquired resistance via increased macrophage-derived insulin-like growth factor-1 (IGF-1) and tumour cell IGF-1 receptors, ultimately enhancing the PI3K pathway.